FDA全球物质注册数据库(FDA Global Substance Registration System)
物质名称VUDALIMAB
异名/同义词ANTI-PD-1/ANTI-CTLA-4 XMAB20717
ANTI-PD1/CTLA4 BISPECIFIC ANTIBODY XMAB20717
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC
PD-1 X CTLA-4 DUAL CHECKPOINT INHIBITOR XMAB20717
VUDALIMAB
VUDALIMAB [INN]
VUDALIMAB [USAN]
VUDALIMAB [WHO-DD]
XMAB20717
XMAB-20717
CAS登记号2329669-72-7
物质唯一标识(Unique Ingredient Identifier)4I9I5X3Z6N
分子式
国际化合物标识(International Chemical Identifier,InChI)
SMILES
分子结构式
欧洲化学品管理局注册号(ECHA)
成分类型INGREDIENT SUBSTANCE / protein
关联数据
  • 药品国际非专利名称数据库
  • 世界卫生组织药物词典
扩展资源
©2006-2024 Drugfuture->FDA Global Substance Registration System